The Indiana Hemophilia and Thrombosis Center (IHTC) was founded in 1998 by two internationally recognized experts, Drs. Amy Shapiro and Anne Greist.
As IHTC expanded, it became one of the nation’s largest hemophilia treatment centers—and, as experts in the care of bleeding disorders, the only center in Indiana to receive federal designation. Now, IHTC delivers patient- and family-centered, comprehensive care for hemophilia, thrombosis, von Willebrand disease, sickle cell disease, and other bleeding and clotting disorders—including rare conditions.
IHTC began with a vision for a center where patients and families affected by blood disorders could receive the best treatment. With extensive experience in hematologic disorders and depth of specialization in the field, our doctors, nurses, and specialists are focused on improving quality of life for our blood disorder patients and their families.
The Indiana Hemophilia & Thrombosis Center (IHTC) is committed to providing the highest quality comprehensive services and holistic care to patients with bleeding, clotting, and other hematologic disorders, and to their families.
A futu...re where people with rare blood disorders flourish
Our Research Department:
Clinical research can improve overall understanding of bleeding and clotting disorders, increase knowledge of genetics, and provide ongoing safety information of therapy. Clinical research studies may offer patients and payors substantial new treatment options and cost savings related to laboratory testing.
The IHTC has a long-standing history of leadership in clinical research, with numerous active studies available to eligible patients. The IHTC performed the world’s first human infusion of the following products:
Genetically engineered factor IX concentrate
Long-acting genetically engineered immunoglobulin fused factor IX concentrate
Genetically engineered von Willebrand factor concentrate
Genetically engineered bio-similar factor IX concentrate
Intravenous Plasminogen (Human) Concentrate
The IHTC independently evaluates the need for each study, weighing above all the project’s safety as well as the potential impact on future patient care. The IHTC coordinates a wide range of clinical research including pharmaceutical, observational, investigator-initiated, quality-of-life analyses, and nationally funded studies (e.g. Centers for Disease Control and Prevention and National Institute of Health).